Close Menu

NEW YORK – Novacyt said on Monday that its molecular test for the COVID-19 virus has received CE marking.

The company's molecular division, Primerdesign, has launched the test, which follows the launch of Novacyt's research-use-only coronavirus test on Jan. 31. Laboratories and hospitals can use the clinical test on patients without the need for validation by clinicians, according to Paris-based Novacyt.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.